Grade group 4 prostate cancer without intraductal carcinoma on biopsy is more likely to be downgraded on prostatectomy than with intraductal carcinoma

被引:0
|
作者
Levent Trabzonlu
Thanchanok Chaiprasit
Andreas Kontosis
Maria Picken
机构
[1] Loyola University Medical Center,Department of Pathology and Laboratory Medicine
[2] Massachusetts General Hospital,Department of Pathology
来源
Virchows Archiv | 2024年 / 484卷
关键词
Prostate cancer; Intraductal carcinoma; Grade group 4; Downgrading;
D O I
暂无
中图分类号
学科分类号
摘要
In this study, we investigated the association between intraductal carcinoma of the prostate (IDCP) along with several histopathological features on prostate biopsy and downgrading of grade group 4 (GG4) prostate cancer (PCa) in patients with the highest grade tumor of GG4 PCa in at least one core. A total of 29 cases had the highest grade tumor of GG4 PCa and radical prostatectomy performed between 2016 and 2021. IDCP was detected in 11 out of 29 cases on biopsy. The cases without IDCP were more likely to be downgraded on prostatectomy than with IDCP, with statistical significance (88.9% vs 36.4%, p = 0.003). The proportions of the highest-grade tumors by length and cores involved, average numbers of PCa-positive cores, and mean patient’s age did not differ between cases that were downgraded and not downgraded at prostatectomy. Our results suggest that the absence of IDCP on biopsy could be a predictor of downgrading at prostatectomy for patients with the highest grade tumor of GG4 PCa.
引用
收藏
页码:517 / 520
页数:3
相关论文
共 50 条
  • [1] Grade group 4 prostate cancer without intraductal carcinoma on biopsy is more likely to be downgraded on prostatectomy than with intraductal carcinoma
    Trabzonlu, Levent
    Chaiprasit, Thanchanok
    Kontosis, Andreas
    Picken, Maria
    [J]. VIRCHOWS ARCHIV, 2024, 484 (03) : 517 - 520
  • [2] Intraductal carcinoma has a minimal impact on Grade Group assignment in prostate cancer biopsy and radical prostatectomy specimens
    Rijstenberg, L. Lucia
    Hansum, Tim
    Hollemans, Eva
    Kweldam, Charlotte F.
    Kummerlin, Intan P.
    Bangma, Chris H.
    van der Kwast, Theodorus H.
    Roobol, Monique J.
    van Leenders, Geert J. L. H.
    [J]. HISTOPATHOLOGY, 2020, 77 (05) : 742 - 748
  • [3] Smoking increased the risk of prostate cancer with grade group ≥ 4 and intraductal carcinoma in a prospective biopsy cohort
    Tang, Bo
    Han, Cheng-Tao
    Gan, Hua-Lei
    Zhang, Gui-Ming
    Zhang, Cui-Zhu
    Yang, Wei-Yi
    Shen, Ying
    Zhu, Yao
    Ye, Ding-Wei
    [J]. PROSTATE, 2017, 77 (09): : 984 - 989
  • [4] Intraductal Carcinoma of the Prostate Without Invasive Carcinoma on Needle Biopsy: Emphasis on Radical Prostatectomy Findings
    Robinson, Brian D.
    Epstein, Jonathan I.
    [J]. JOURNAL OF UROLOGY, 2010, 184 (04): : 1328 - 1333
  • [5] Grading of intraductal carcinoma has minor impact on grade group assignment in prostate cancer biopsy and radical prostatectomy specimens
    Rijstenberg, L.
    Hollemans, E.
    Hansum, T.
    Kweldam, C.
    van Leenders, G.
    [J]. VIRCHOWS ARCHIV, 2020, 477 : S3 - S3
  • [6] Intraductal Carcinoma of the Prostate: To Grade or Not to Grade
    Surintrspanont, Jerasit
    Zhou, Ming
    [J]. CANCERS, 2023, 15 (22)
  • [7] Grading of Intraductal Carcinoma of the Prostate: Impact on Overall Grade Group Assignment at Diagnostic Biopsy
    Chen-Maxwell, Daphne
    Prendeville, Susan
    [J]. LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 874 - 875
  • [8] Grading of Intraductal Carcinoma of the Prostate: Impact on Overall Grade Group Assignment at Diagnostic Biopsy
    Chen-Maxwell, Daphne
    Prendeville, Susan
    [J]. MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 874 - 875
  • [9] Needle biopsy and intraductal prostate carcinoma
    不详
    [J]. PROSTATE CANCER AND PROSTATIC DISEASES, 2006, 9 (04) : 366 - 366
  • [10] The impact of intraductal carcinoma of the prostate on the grade group system.
    Kato, Masashi
    Yamamoto, Akiyuki
    Ishida, Ryo
    Kimura, Tohru
    Sano, Tomoyasu
    Gotoh, Momokazu
    Tsuzuki, Toyonori
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)